Intervention/Treatment: The trial tests Itepekimab, administered subcutaneously in high and low doses, alongside Mometasone furoate nasal spray. The purpose is to improve symptoms in patients with ...

Regeneron Pharmaceuticals delivered strong Q2 results and made net progress with its commercial portfolio and pipeline. Click ...

On May 30, 2025, Sanofi issued a press release announced mixed data from a Phase 3 program for itepekimab, an antibody therapy targeting the lung disorder chronic obstructive pulmonary disease.

Sanofi’s commitment to sustainability has been recognized globally, with TIME ranking it as the world’s 10th most sustainable company across all industries and #1 in pharma and biotech. This accolade ...

In 2025, sales are anticipated to grow by a high single-digit percentage at CER (previously mid-to-high single-digit). Sanofi confirms the expectation of a strong business EPS rebound with growth at a ...

Q2 2025 Earnings Call Transcript August 1, 2025 Regeneron Pharmaceuticals, Inc. beats earnings expectations. Reported EPS is ...

Second quarter 2025 revenues increased 4% to $3.68 billion versus second quarter 2024Dupixent® global net sales (recorded by Sanofi) increased 22% to $4.34 billion EYLEA HD® U.S. net sales increased ...

French pharmaceutical company Sanofi said it is acquiring London-based Vicebio to expand its range of respiratory virus vaccines and add a non-mRNA vaccine to its pipeline.

Sanofi has struck a deal to buy Vicebio for $1.15 billion upfront, securing a phase 1 vaccine candidate to expand its RSV pipeline beyond mRNA.

Sanofi acquires Vicebio for $1.15 billion, adding a next-gen RSV-hMPV vaccine and ‘Molecular Clamp' tech to strengthen its respiratory vaccine pipeline.